Target Group (CBDY) Fair Value & Analysis
Healthcare · US · Market cap $926K
Target Group
CBDY · US
Fair value as of: Jun 26, 2026
From 6 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0500 to $0.0014 (−97.2%) since Jun 24, 2026. Share price −20.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0011 – $0.0035 · fair‑value band $0.0014 – $0.0014 · the $0.0014 price screens below the $0.0014 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Target Group (CBDY) currently trades at $0.0014, while our model-based Fair Value estimate is $0.0014 — implying the stock looks roughly 0.1% undervalued today. We read business quality at 33/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Target Group generated revenue of $3.4M at a net margin of -53.6%. Revenue declined 37.2% year over year. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Target Group Inc. engages in the cultivation, processing, and distribution of curated cannabis products for the medical and adult-use recreational cannabis market in Canada and the United States. The company offers cannabis pre-rolls, and flower and extract pods for vaporizer use; K-Cup infused coffee and tea pods; and infused cannabis beverages, edibles, and topical products and CBD wellness products. It also provides a single-use pre-measured pod and vaporizer system for consumers interested in vaporizing natural herbs, including cannabis under The Wisp and Wisp Pods brands. The company was formerly known as Chess Supersite Corporation and changed its name to Target Group Inc. in July 2018. Target Group Inc. was incorporated in 2013 and is based in Hamilton, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Target Group reported revenue of $3.9M in FY2025 versus $0 in FY2021. Reported net income was −$1.4M in FY2025.
Is CBDY fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Target Group (CBDY) undervalued?
What is the fair value of CBDY?
What is the quality score of CBDY?
What is the revenue of Target Group (CBDY)?
What is the net profit margin of CBDY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.